Are inhaled corticosteroids indicated as the first-line monotherapy for COPD?

Inhaled corticosteroids (ICS) are not indicated as first-line monotherapy for Chronic Obstructive Pulmonary Disease (COPD). The primary treatment for COPD typically involves the use of bronchodilators, including long-acting beta-agonists (LABAs) or long-acting muscarinic antagonists (LAMAs), due to their effectiveness in relieving symptoms and improving lung function.

While ICS can be a valuable part of the treatment plan, especially in patients with frequent exacerbations or those who exhibit features of asthma-COPD overlap, they are generally not utilized as the sole treatment option. Instead, they are often combined with bronchodilators to maximize therapeutic benefits. Therefore, they are not considered first-line monotherapy.

Patients with COPD may require personalized treatment plans, and the decision to include ICS will depend on factors such as exacerbation history and individual patient characteristics. This helps underscore the correct viewpoint that is aligned with current clinical guidelines.